Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

ASPIRE (Stroke Prevention) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to compare 2 different options for preventing strokes for people who have atrial fibrillation. We want to find out if apixaban or aspirin is the better choice to help prevent future strokes for patients with atrial fibrillation and who had a recent brain hemorrhage.

What is the Condition Being Studied?

Stroke and Atrial Fibrillation

Who Can Participate in the Study?

Adults ages 18+ who:

  • Had an intracerebral hemorrhage (including primary intraventricular hemorrhage) within the past 180 days
  • Are diagnosed with non-valvular AF (defined as atrial fibrillation or atrial flutter)

For more information about this study, contact the study team at megan.gonzalez@duke.edu.

Age Group
Adults

What is Involved?

If you choose to join this study, we will schedule you for a "baseline" visit that you can do in-person or over the phone or computer. If we determine that you are eligible to continue in the study, you will get a random assignment (like a coin flip) to 1 of 2 study groups. Depending on your assignment, you will either:

  • Take an 81 mg dose of aspirin every day; OR
  • Take a 5 or 2.5 mg dose of apixaban twice per day (your dose will depend on your age, weight, and kidney function)

The study is "blind," which means you will not know your group assignment. Everyone in the study will take a combination of real pills and placebo (inactive "sugar pills") every day. The combination will either be legitimate aspirin and placebo or legitimate apixaban and placebo. However, if it ever becomes medically necessary to know your group assignment, the research team can unblind your assignment and let you and your doctor(s) know what you are taking.

Participation in the study will last for up to 3 years. You will have check-up visits with the study doctor and study team every 3 months while you are in the study. These visits will take 15-30 minutes. If in-person visits are not possible, you can do the visits over the phone or computer. Activities at these routine follow-up visits will include:

  • Assessing for any strokes or adverse events since your last visit
  • Assessing how well you are taking your study medications
  • Assessing your physical health
  • Assessing what other medications you are taking
  • Assessing your blood pressure
  • Providing you with a re-supply of the study medications

If a follow-up visit is not done in-person for any reason, your new supply may be mailed to your home from the site pharmacy. The study staff will still need to collect all unused study medication, so please save all bottles and unused medication until they can be returned.

Study Details

Full Title
Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery
Principal Investigator
Neurologist
Protocol Number
IRB: PRO00116346
NCT: NCT03907046
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
Open for Enrollment Soon